Search clinical trials for: JNJ-75276617

Total 1088 results

Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Pain | Mononeuropathies | Neuralgia | Neuralgia, Postherpetic

United States, Spain, Belgium, Netherlands
Janssen Research & Development, LLC

Terminated

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Healthy

Belgium
Janssen Sciences Ireland UC

Completed

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

Belgium, United Kingdom, France, Italy, Germany, Spain, Poland
Janssen Research & Development, LLC

Recruiting

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

United States, United Kingdom, Korea, Republic of, Taiwan, Canada, Denmark, France, Thailand, New Zealand, Spain, China, Israel, Germany, Colombia, India, Netherlands, Australia, Japan, Sweden, Czechia, Italy
Janssen Research & Development, LLC

Completed

A Study of JNJ-67835989 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Neoplasm

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-70075200 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants

Healthy

Germany
Janssen-Cilag International NV

Completed

Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Pain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, Splitting

United States, France, Spain, Poland, Portugal
Janssen Research & Development, LLC

Completed

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

Major Depressive Disorder

Ukraine, Bulgaria, Romania, Russian Federation, Hungary, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostatic Neoplasms

Canada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
Janssen Research & Development, LLC

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Multiple Myeloma

United States, Belgium, China, Israel, Netherlands, Spain, Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Urologic Diseases | Urinary Bladder Diseases | Cystitis | Cystitis, Interstitial

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Pain | Osteoarthritis | Joint Pain | Arthralgia | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Canada, Korea, Republic of
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Janssen Sciences Ireland UC

Terminated

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Virus Diseases | Respiratory Syncytial Virus Infections

Australia, Spain, Belgium, Sweden, Netherlands, Brazil, Germany, Argentina, Philippines, United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Janssen Research & Development, LLC

Completed

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous

France, United Kingdom, Spain, Portugal, United States, Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy

Arthritis, Rheumatoid

Poland, Ukraine, Chile, Korea, Republic of, Singapore, Russian Federation, Argentina, Bulgaria, Hungary, Czech Republic
Janssen Research & Development, LLC

Completed

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States, Taiwan, Japan, Korea, Republic of, France, Mexico, Brazil, Sweden, Argentina, Ukraine, Canada, Spain, Germany, Poland, Belgium, Russian Federation, South Africa, Australia, Bulgaria
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (DHODH)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United Kingdom, France, Korea, Republic of, Spain
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever

Dengue

Singapore
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)

COVID-19 Prevention

United States, South Africa, Brazil
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

Multiple Myeloma

China
Lung Cancer Group Cologne

Terminated

FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)

NSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary Neoplasm

Germany
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Multiple Myeloma

China
Janssen Research & Development, LLC

Completed

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Neoplasms | Colorectal Cancer | Advanced Solid Tumors | Non-small Cell Lung Cancer

France, United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

Healthy

Philippines
Janssen Research & Development, LLC

Active, not recruiting

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

Denmark, France, Poland, Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Healthy | Renal Insufficiency

United States
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Janssen Research & Development, LLC

Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Korea, Republic of, United States, Germany, Spain, Netherlands
Zujiang YU

Not yet recruiting

Prevention of Cancer Development and Progression

Cancer
Rabin Medical Center
Janssen, LP

Recruiting

Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

Central Nervous System Lymphoma

Israel
Janssen Research & Development, LLC

Completed

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

Depressive Disorder, Major

United States, Taiwan, Czechia, Spain, Mexico, South Africa, Colombia, Russian Federation, Brazil, Bulgaria, Sweden
Actelion

Terminated

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (RESTORE)

Pulmonary Arterial Hypertension

Germany, Korea, Republic of, Israel, Singapore, United States, Russian Federation, Brazil, Netherlands, Malaysia, Saudi Arabia, United Kingdom, Hong Kong, France, United Arab Emirates, Argentina
Janssen Research & Development, LLC

Completed

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

Healthy

United States
Octimet Oncology N.V.

Terminated

OMO-1 in Solid Malignancies

Neoplasms

France, United Kingdom, Netherlands, United States, Belgium
Janssen Vaccines & Prevention B.V.

Completed

A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

Healthy

Belgium
Janssen R&D Ireland

Terminated

Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

Chronic Hepatitis C Infection

Germany
Janssen Research & Development, LLC

Completed

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, France, Ukraine, Germany, Israel, Poland, Bulgaria, Romania, Russian Federation, Canada, Netherlands, Belgium, Hungary
Janssen Research & Development, LLC

Completed

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

Healthy Male Volunteer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Prostatic Neoplasms

United States, France, Spain, Netherlands
Janssen Research & Development, LLC

Recruiting

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

United States, Netherlands, Spain, France, Sweden

3

Subscribe